Journal
NEURO-ONCOLOGY
Volume 23, Issue 2, Pages 264-276Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/noaa156
Keywords
CDKN1A; HIF1A; glioblastoma; miR-93-5p; regorafenib
Categories
Funding
- Veneto Institute of Oncology IOV-IRCSS, Padua, Italy (IOV Intramural Grant 5x1000 Genomica dei Tumori)
- Brain Research Foundation of Verona, Verona, Italy
- Fondazione Luca Ometto, Padova, Italy
Ask authors/readers for more resources
The study identified a signature based on the expression of 5 biomarkers that could help identify a subgroup of GBM patients exhibiting a striking survival advantage when treated with regorafenib. Further validation in larger replication cohorts is needed, but potential biomarker options have been highlighted to guide clinical decision-making between regorafenib and other treatments in patients with relapsing GBM.
Background. Patients with glioblastoma (GBM) have a dramatically poor prognosis. The recent REGOMA trial suggested an overall survival (OS) benefit of regorafenib in recurrent GBM patients. Considering the extreme genetic heterogeneity of GBMs, we aimed to identify molecular biomarkers predictive of differential response to the drug. Methods. Total RNA was extracted from tumor samples of patients enrolled in the REGOMA trial. Genome-wide transcriptome and micro (mi)RNA profiles were associated with patients' OS and progression-free survival. Results. In the first step, a set of 11 gene transcripts (HIF1A, CTSK, SLC2A1, KLHL12, CDKN1A, CA12, WDR1, CD53, CBR4, NIFK-AS1, RAB30-DT) and 10 miRNAs (miR-93-5p, miR-203a-3p, miR-17-5p, let-7c-3p, miR-101-3p, miR-3607-3p, miR-6516-3p, miR-301a-3p, miR-23b-3p, miR-222-3p) was filtered by comparing survival between regorafenib and lomustine arms. In the second step, a mini-signature of 2 gene transcripts (HIF1A, CDKN1A) and 3 miRNAs (miR-3607-3p, miR-301a-3p, miR-93-5p) identified a subgroup of patients showing prolonged survival after regorafenib administration (median OS range, 10.6-20.8 mo). Conclusions. The study provides evidence that a signature based on the expression of 5 biomarkers could help identify a subgroup of GBM patients exhibiting a striking survival advantage when treated with regorafenib. Although the presented results must be confirmed in larger replication cohorts, the study highlights potential biomarker options to help guide the clinical decision among regorafenib and other treatments in patients with relapsing GBM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available